A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Absolute neutrophil count ≤1.5 X 109/L
• •Platelet count ≤ 50 X 109/L
• •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 3 X upper limit of normal (ULN) (\>5 × ULN if due to cGVHD)
• •Total bilirubin ≥ 1.5 X ULN
• •Glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m3
• •Positive hepatitis B surface antigen, or hepatitis C antibody or HIV antibody at screening
• •FEV1 ≤39% or has lung score of 3
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.